Gastric Cancer

, Volume 6, Supplement 1, pp 2–8 | Cite as

S-1 in gastric cancer: a comprehensive review

  • Yoshihiko Maehara
Review article


The current basic and clinical studies of S-1 (TS-1®) were reviewed. S-1 is a novel oral dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine (DIF) based on a biochemical modulation of 5-fluorouracil (5-FU); S-1 contains tegafur (FT) and two types of enzyme inhibitor; 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) in a molar ratio of 1 : 0.4 : 1. In pharmacokinetic studies, S-1 showed high 5-FU concentration in blood for long periods of time. In a combined analysis of two pivotal late phase II studies in gastric cancer, the overall response rate was 44.6% (45/101), and median survival time and 1-year survival rate were 244 days and 37%, respectively. A postmarketing survey was conducted, and in the interim analysis, tolerability and safety profiles were shown in 3294 patients with gastric cancer. The oral dose form and low incidence of adverse reactions permit treatment on an outpatient basis. To evaluate the survival benefit of S-1 in advanced gastric cancer, a phase III study of S-1 vs 5-FU vs cisplatin (CDDP) plus irinotecan (CPT-11) has been conducted. The effect of S-1 in adjuvant chemotherapy is also promising. Currently, a phase III study of surgery alone vs S-1 in patients with curative resection of gastric cancer is in progress. Further therapeutic benefits are expected to be gained by combining S-1 with other chemotherapeutic agents. Several preliminary results of combination phase I/II studies of S-1 with CDDP or CPT-11 have recently been obtained, and phase II studies are in progress. Thus, S-1 is currently the first candidate as the standard anticancer drug for gastric cancer. Further evaluations by well-controlled clinical trials are still needed.

Key words

S-1 Gastric cancer Comprehensive review 


  1. 1.
    Grem, JL 20005-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical developmentInvest New Drugs18299313PubMedCrossRefGoogle Scholar
  2. 2.
    Analysis, Meta 1998Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced cancerJ Clin Oncol163018Google Scholar
  3. 3.
    Analysis, Meta 1998Group in Cancer. Toxicity of fluorouracil in patients with advanced gastric cancer: effect of administration schedule and prognostic factorsJ Clin Oncol16353741Google Scholar
  4. 4.
    Moynihan, T, Hansen, R, Anderson, T, Quebbeman, E, Beatty, P, Ausman, R,  et al. 1998Continuous 5-fluorouracil infusion in advanced gastric carcinomaAm J Clin Oncol114614Google Scholar
  5. 5.
    Shirasaka, T, Shimamoto, Y, Ohshimo, H, Yamaguchi, M, Kato, T, Yonekura, K,  et al. 1996Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulatorsAnticancer Drugs754857PubMedGoogle Scholar
  6. 6.
    Toide, H, Akiyoshi, H, Minato, Y, Okuda, H, Fujii, S 1977Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracilGann6855360PubMedGoogle Scholar
  7. 7.
    Fujii, S, Shimamoto, Y, Ohshimo, H, Imaoka, T, Motoyama, M, Fukushima, M,  et al. 1989Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in ratsJpn J Cancer Res8016772PubMedGoogle Scholar
  8. 8.
    Fujii, S, Kitano, S, Ikenaka, K, Fukushima, M, Shirasaka, T 1979Co-administration of uracil or sytosine on antitumor activity of FT207 or 5-FU derivativesJpn J Cancer Chemother61097103Google Scholar
  9. 9.
    Takiuchi, H, Ajani, JA 1998Uracil-Tegafur in gastric carcinoma: a comprehensive reviewJ Clin Oncol16287785PubMedGoogle Scholar
  10. 10.
    Carmichael, J, Popiela, T, Radstone, D, Falk, S, Borner, M, Oza, A,  et al. 2002Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol20361727PubMedCrossRefGoogle Scholar
  11. 11.
    Douillard, JY, Hoff, PM, Skillings, JR, Eisenberg, P, Davidson, N, Harper, P,  et al. 2002Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol20360516PubMedCrossRefGoogle Scholar
  12. 12.
    Tatsumi, K, Fukushima, M, Shirasaka, T, Fujii, S 1987Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extractsJpn J Cancer Res7874855PubMedGoogle Scholar
  13. 13.
    Shirasaka, T, Nakano, K, Takechi, T, Satake, H, Uchida, J, Fujioka, A,  et al. 1996Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude ratsCancer Res5626026PubMedGoogle Scholar
  14. 14.
    Takechi, T, Fujioka, A, Matsushima, E, Fukushima, M 2002Enhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyrimidine (CDHP) in human tumour cellsEur J Cancer3812717PubMedCrossRefGoogle Scholar
  15. 15.
    Foenig, H, Patel, A 1970Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fluoroacetateArch Neurol2315560Google Scholar
  16. 16.
    Sobrero, A, Kerr, D, Glimelius, B, Cutsem, EV, Milano, G, Pritchard, DM,  et al. 2000New directions in the treatment of colorectal cancer: a look to the futureEur J Cancer3655966PubMedCrossRefGoogle Scholar
  17. 17.
    Shirasaka, T, Shimamoto, Y, Fukushima, M 1993Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in ratsCancer Res5340049PubMedGoogle Scholar
  18. 18.
    Kato, T, Shimamoto, Y, Uchida, J, Ohshimo, H, Abe, M, Shirasaka, T,  et al. 2001Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracilAnticancer Res21170512PubMedGoogle Scholar
  19. 19.
    Fukushima, M, Satake, H, Uchida, J, Shimamoto, Y, Kato, T, Takechi, T,  et al. 1998Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenograftsInt J Oncol136938PubMedGoogle Scholar
  20. 20.
    Taguchi, T, Inuyama, Y, Kanamaru, R, Hasegawa, K, Akazawa, S, Niitani, H,  et al. 1997Phase I study of S-1Jpn J Cancer Chemother24225364Google Scholar
  21. 21.
    Sugimachi, K, Maehara, Y, Horikoshi, N, Shimada, Y, Sakata, Y, Mitachi, Y,  et al. 1999An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancersOncology5720210PubMedCrossRefGoogle Scholar
  22. 22.
    Ohtsu, A, Baba, H, Sakata, Y, Mitachi, Y, Horikoshi, N, Sugimachi, K,  et al. 2000Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinomaBr J Cancer831415PubMedGoogle Scholar
  23. 23.
    Taguchi, T, Morimoto, K, Horikoshi, N, Takashima, S, Toge, T, Kimura, M,  et al. 1998An early phase II clinical study of S-1 in patients with breast cancerJpn J Cancer Chemother25103543Google Scholar
  24. 24.
    Inuyama, Y, Kida, A, Tsukuda, M, Kohno, N, Satake, B 1998Early phase II study of S-1 in patients with advanced head and neck cancerJpn J Cancer Chemother2511518Google Scholar
  25. 25.
    Furuse, K, Kawahara, M, Hasegawa, K, Kudoh, S, Takada, M, Sugiura, T,  et al. 2001Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancerInt J Clin Oncol623641PubMedGoogle Scholar
  26. 26.
    Sakata, Y, Ohtsu, A, Horikoshi, N, Sugimachi, K, Mitachi, Y, Taguchi, T 1998Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patientsEur J Cancer34171520PubMedCrossRefGoogle Scholar
  27. 27.
    Koizumi, W, Kurihara, M, Nakano, S, Hasegawa, K 2000Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancerOncology581917PubMedCrossRefGoogle Scholar
  28. 28.
    Niitani, H, Kurihara, M, Saito, T, Nakao, I, Abe, O, Urushizaki, I,  et al. 1985Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer — multi-institutional cooperative studyJpn J Cancer Chemother12204451Google Scholar
  29. 29.
    Ishibiki, K, Kumai, K, Kodaira, S, Abe, O, Yamamoto, K, Ouchi, T,  et al. 1989Phase II study with cisplatin in advanced stomach and colon cancerJpn J Cancer Chemother16318593Google Scholar
  30. 30.
    Futatsuki, K, Wakui, A, Nakao, I, Sakata, Y, Kambe, M, Shimada, Y,  et al. 1994Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancerJpn J Cancer Chemother2110338Google Scholar
  31. 31.
    Taguchi, T, Sakata, Y, Kanamaru, R, Kurihara, M, Suminaga, M, Ota, J,  et al. 1998Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperatative Study Group Trial (Group A)Jpn J Cancer Chemother25191524Google Scholar
  32. 32.
    Mai, M, Sakata, Y, Kanamaru, R, Kurihara, M, Suminaga, M, Ota, J,  et al. 1999A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a Japanese Cooperatative Study Group Trial (Group B)Jpn J Cancer Chemother2648796Google Scholar
  33. 33.
    Yamaguchi, K, Tada, M, Horikoshi, N, Otani, T, Takiuchi, H, Saitoh, S,  et al. 2002Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancerGastric Cancer5905PubMedCrossRefGoogle Scholar
  34. 34.
    Yamada, Y, Shirao, K, Ohtsu, A, Boku, N, Hyodo, I, Saitoh, H,  et al. 2001Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis of paclitaxel-associated hypersensitivity reactionsAnn Oncol1211337PubMedCrossRefGoogle Scholar
  35. 35.
    Hirata, K, Horikoshi, N, Aiba, K, Okazaki, M, Denno, R, Sasaki, K,  et al. 2000Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drugClin Cancer Res520005Google Scholar
  36. 36.
    Yamada, K, Shirao, Y, Matsumura, K, Muro, M, Goto, T, Hamaguchi, Y,  et al. 2001Comparison of 5-fluorouracil and F-β-alanin pharmacokinetics in patients receiving protracted venous infusion of 5-fluorouracil and oral S-1 (abstract)Proc Am Soc Clin Oncol2091aGoogle Scholar
  37. 37.
    Ohtsu, A, Boku, N, Nagashima, F, Koizumi, W, Tanabe, S, Saigenji, K,  et al. 2001A phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (ACG) (abstract)Proc Am Soc Clin Oncol20165aGoogle Scholar
  38. 38.
    Narahara, H, Takiuchi, H, Tsujinaka, T, Furukawa, H, Taguchi, T 2002Phase I study of CPT-11 plus S-1 in patients with metastatic gastric cancer (abstract)Proc Am Soc Clin Oncol21170aGoogle Scholar
  39. 39.
    Komatsu, Y, Takeda, H, Masaaki, T, Kato, T, Tateyama, M, Miyagishima, T,  et al. 2002A phase I and PK study of S-1 and irinotecan (CPT-11) in patients with advanced gastric cancer (AGC) (abstract)Proc Am Soc Clin Oncol21171aGoogle Scholar
  40. 40.
    Nagashima F, Ohtsu A, Boku N, Yoshida S, Itoh K, Sano M. Japanese nation-wide post marketing survey of S-1 in patients with advanced gastric Cancer. 4th International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, September 6–8, 2001, Koln, GermanyGoogle Scholar
  41. 41.
    Ikeda, M, Furukawa, H, Imamura, H, Shimizu, J, Ishida, H, Masutani, S,  et al. 2002Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal functionCancer Chemother Pharmacol502532PubMedCrossRefGoogle Scholar
  42. 42.
    Yoshikawa, T, Kanari, M, Tsuburaya, A, Kobayashi, O, Sairenji, M, Motohashi, H,  et al. 2000Advanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapyGastric Cancer31715PubMedGoogle Scholar
  43. 43.
    Kurakawa, E, Kasuga, I, Ishizuka, S, Yoshida, T, Kunisawa, A, Minemura, K,  et al. 2001Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case reportJpn J Clin Oncol312846PubMedCrossRefGoogle Scholar
  44. 44.
    Tsukioka, Y, Matsumura, Y, Hamaguchi, T, Goto, M, Muro, K, Yamada, Y,  et al. 2001Complete response achieved following administration of S-1 in a patient with adrenal gland metastasis of 5-FU-resistant gastric cancer: a case reportJpn J Clin Oncol314503PubMedCrossRefGoogle Scholar
  45. 45.
    Osugi, H, Takada, N, Takemura, M, Kaseno, S, Lee, S, Ueno, M,  et al. 2002Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal disseminationOncol Rep98115PubMedGoogle Scholar
  46. 46.
    Kobayashi, O, Konishi, K, Kanari, M, Cho, H, Yoshikawa, T, Tsuburaya, A,  et al. 2002Unusual survival for more than 2 years with peritoneal metastases of gastric cancerGastric Cancer54750PubMedGoogle Scholar
  47. 47.
    Iwazawa, T, Kinuta, M, Yano, H, Matsui, S, Tamagaki, S, Yasue, A,  et al. 2002An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resectionGastric Cancer596101PubMedCrossRefGoogle Scholar
  48. 48.
    Watanabe, S, Tanaka, T, Takeuchi, T, Takabayashi, H, Hirayama, Y 2002Advanced gastric cancer with liver metastases successfully treated with S-1Int J Clin Oncol73269PubMedGoogle Scholar
  49. 49.
    Ajani, JA, Ota, DM, Jackson, DE 1991Current strategies in the management of locoregional and metastatic gastric cancerCancer672605PubMedGoogle Scholar
  50. 50.
    Schipper, DL, Wagener, DJ 1996Chemotherapy of gastric cancerAnticancer Drugs713749PubMedGoogle Scholar
  51. 51.
    Tahara, M, Ohtsu, A 2000Latest progress on chemotherapy for advanced gastric cancerJpn J Cancer Chemother27204858Google Scholar

Copyright information

© International and Japanese Gastric Cancer Associations 2003

Authors and Affiliations

  • Yoshihiko Maehara
    • 1
  1. 1.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations